Key result
Glycosaminoglycans produce a ~2-fold increase in ex vivo thrombin inactivation, indicating reliable antithrombotic potential.
Why the study?
Does the catalysis of thrombin inhibition by plasma serve as a reliable index for estimating the antithrombotic potential of glycosaminoglycans in rabbits?
Population
Rabbits and in vitro plasma samples
Comparison
Glycosaminoglycans vs Control plasma
Design
Preclinical
Authors
Loading...
Validates thrombin inactivation assay for glycosaminoglycan screening in rabbits; leaves open translation to human antithrombotic assessment.
Does the catalysis of thrombin inhibition by plasma serve as a reliable index for estimating the antithrombotic potential of glycosaminoglycans in rabbits?
Effect estimate: approximately a 2-fold increase
Measurement of the catalysis of thrombin inactivation in undiluted plasma provides a sensitive and reliable index for estimating the antithrombotic potential of glycosaminoglycans in rabbits.
Fernandez et al. (1987) studied Antithrombotic potential assessment. Glycosaminoglycans vs. Control plasma was evaluated on Amount of thrombin inactivated 30 s after addition to plasma (approximately a 2-fold increase). Ex vivo plasmas from rabbits injected with glycosaminoglycans showed an approximate 2-fold increase in thrombin inactivation, suggesting this assay is a reliable index for antithrombotic potential.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: